- Home
- NMAI vs SOPH Comparison
NMAI vs SOPH Comparison
Compare NMAI & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | SOPH |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.3M | 367.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NMAI | SOPH |
|---|---|---|
| Price | $13.72 | $4.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 112.2K | ★ 192.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $18.48 |
| Revenue Next Year | N/A | $16.25 |
| P/E Ratio | $21.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.21 | $2.58 |
| 52 Week High | $13.96 | $5.70 |
Technical Indicators
Market Signals| Indicator | NMAI | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 40.11 |
| Support Level | $12.72 | $4.54 |
| Resistance Level | $13.96 | $4.85 |
| Average True Range (ATR) | 0.16 | 0.26 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 47.86 | 6.15 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.